• Earlier this week, Cardinal Health reported Q3 fiscal 2026 results that exceeded estimates and raised its full-year adjusted EPS and free cash flow guidance, alongside updates on theranostics expansion and a voluntary recall of certain alcohol prep pads.
• The combination of upgraded outlook and continued investment in its Center for Theranostics Advancement highlighted management’s confidence in Cardinal Health’s higher-value growth initiatives, even as the company managed operational and quality-control challenges.
• Now we’ll examine how Cardinal Health’s upgraded earnings guidance and free cash flow outlook may reshape the company’s longer-term investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.

Cardinal Health Investment Narrative Recap

To own Cardinal Health, you need to be comfortable with a large-scale distributor that is trying to tilt more of its business toward higher-margin healthcare services and specialty solutions, while still facing regulatory, pricing and contract risks. The stronger Q3 earnings and higher EPS and free cash flow guidance support that thesis in the near term, but the recent share price move and mixed analyst calls suggest the most immediate swing factor is how investors reassess valuation, not a fundamental shift in risk.

The Q3 update around continued expansion of the Center for Theranostics Advancement is particularly relevant here, as it sits at the heart of Cardinal Health’s push into specialty and nuclear medicine, one of the key higher-value growth areas underpinning the long-term catalyst story. At the same time, the alcohol prep pad recall is a reminder that product quality and regulatory scrutiny remain ever-present and can quickly refocus attention on execution and compliance.

But while growth initiatives in theranostics look appealing, investors should also be aware of the risk that increasing government regulation and pricing scrutiny could...

Cardinal Health's narrative projects $314.4 billion revenue and $2.3 billion earnings by 2029. This requires 7.8% yearly revenue growth and about a $0.7 billion earnings increase from $1.6 billion today.

Uncover how Cardinal Health's forecasts yield a $245.27 fair value, a 19% upside to its current price.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community span roughly US$190 to US$466 per share, showing how far apart expectations can be. Against that wide range, Cardinal Health’s recent earnings beat and upgraded cash flow outlook place more weight on whether its higher-margin specialty and theranostics efforts can offset ongoing regulatory and pricing pressures, so it helps to compare several independent views before deciding how this fits into your portfolio.

Explore 4 other fair value estimates on Cardinal Health - why the stock might be worth 8% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Cardinal Health research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Cardinal Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cardinal Health's overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Outshine the giants: these 13 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.